Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update

Back to Jobs

OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020 OTIPRIO ®  co-promotion agreement completed with Glenmark Therapeutics OTIVIDEX™  Phase 3 trial in Ménière’s disease on track for results in first half of 2020 OTO-413 Phase 1/2 trial in hearing loss expected to

Apply Now